Table 1.
Demographic and Disease Characteristics of the Sample
| Variable | Total Sample N = 466 | APOE4 Carrier n = 144 | APOE4 Noncarrier n = 322 | p |
|---|---|---|---|---|
| Age (M, SD) | 44.1 (8.4) | 44.3 (8.1) | 44.0 (8.6) | .75 |
| Education (M, SD) | 13.0 (2.5) | 12.8 (2.5) | 13.0 (2.4) | .38 |
| % Male | 78.8% | 77.1% | 79.5% | .56 |
| % Caucasian | 50% | 39.6% | 55.0% | .002 |
| % cART | 69.5% | 68.8% | 69.9% | .92 |
| % AIDS | 61.1% | 58.7% | 62.1% | .49 |
| % Detectable CSF VL | 30.1% | 30.2% | 30.0% | .97 |
| % Detectable Plasma VL | 53.1% | 50.7% | 54.2% | .49 |
| Duration infection (Mo)1 | 124.8 [56.9, 183.4] | 122 [59, 180] | 126 [52, 185] | .68 |
| Nadir CD41 | 175 [50.3, 299] | 193 [45, 333] | 162 [55, 286] | .39 |
| % HCV | 27.0% | 31.5% | 24.9% | .15 |
| Comorbidity rating (% Incidental) | 68.2% | 66.7% | 68.9% | .63 |
Note. cART = combined antiretroviral therapy; CSF VL = cerebrospinal fluid viral load; plasma VL = plasma viral load; HCV = hepatitis C infection; Incidental comorbidity rating reflects likelihood that observed neurocognitive impairment was due to HIV infection versus contributing or confounding comorbid conditions [35];
1
data are presented as median [interquartile range] and p-values are based on Wilcoxon Rank-Sum test